香港開啟全民檢測,中國生物科技服務(8037.HK)旗下全港最大新冠檢測機構為香港抗疫作出主要貢獻
格隆匯8月28日丨香港政府已公佈普及社區檢測計劃細節及具體安排,計劃於9月1日正式開展,為期7天,視進度再延長不超過7天至9月14日。市民明日(29日)早上7時起可在網上預約。詳情請瀏覽鏈接(https://www.communitytest.gov.hk/)
據悉,香港上市公司中國生物科技服務(8037.HK)正持續不斷的擴大新冠檢測業務的佈局。
2020年上半年,為了滿足香港與內地的通關需求,公司取得了英諾特授權的“新冠抗體檢測試劑盒”海外分銷權,並推出新冠核酸檢測(自願)項目,早期的核酸檢測量大致為每日600人。另外,公司成為了華大基因的分銷商,獲得了向海外銷售新冠核酸檢測試劑盒的授權。
伴隨着香港疫情再次爆發,新冠檢測需求激增,公司除了銷售新冠核酸檢測試劑盒之外,還與國內頂尖檢測機構進行合資成立新冠檢測實驗室。
2020年6月,中國生物科技服務與華大健康香港有限公司及香港前醫管局主席、現任全國政協常委胡定旭先生成立了華昇診斷中心(SUNRISE),引進華大基因的火眼實驗室,成為香港目前新冠核酸檢測規模最大的一家機構,也是香港擁有高檢測能力的新冠檢測實驗室之一。
另外,根據公司在8月18日的公告顯示,為提高檢測速度,為抗疫保駕護航,公司在香港政府配合下額外設立及經營一間有16個氣膜的臨時實驗室,並在國家檢測支援隊幾百人的大力支持下為香港市民提供新冠檢測。額外的實驗室每日可進行約10萬次單管測試,將使得華昇診斷中心(SUNRISE)由每天的檢測量3萬人份增至13萬人份。
由於香港能夠提供新冠核酸檢測的公司較少,且中國生物科技服務公司的是香港規模最大的一家機構,公司本身業務又具備優良的精準診斷基因,在市場競爭中,新冠檢測業務將使得公司知名度和市場份額都大幅提高。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.